Refractory metastatic colorectal cancer (mCRC) of the microsatellite-stable, mismatch-repair-proficient (MSS/pMMR) subtype remains one of oncology’s most persistent treatment gaps. This subtype accounts for roughly 95% of mCRC cases and has resisted PD-1 checkpoint blockade for over a decade. Successive monotherapy and first-generation combination trials have confirmed what the biology predicts: cold tumors do not respond to PD-1 inhibition alone. After patients exhaust fluoropyrimidine, oxaliplatin, and irinotecan, third-line mCRC options narrow sharply, with median overall survival often measured in just 6–7 months.
Into this gap steps Agenus‘ BOT+BAL — botensilimab plus balstilimab — a next-generation CTLA-4/PD-1 combination now entering pivotal evaluation through the BATTMAN trial. After a quarter that resolved nearly every legal and financial overhang weighing on the company, Agenus has shifted from defending its past to executing on what may be the most clinically advanced bet in refractory MSS/pMMR mCRC.
BATTMAN Trial at a Glance
- Trial name: BATTMAN (CCTG CO.33)
- Phase: 3 (pivotal)
- Treatment arm: BOT+BAL (botensilimab + balstilimab) vs. best supportive care
- Patient population: Refractory MSS/pMMR metastatic colorectal cancer
- Enrollment target: ~830 patients across 100+ sites
- Geographic reach: Canada, France, Australia, and New Zealand
- Primary endpoint: Overall survival
- Enrollment opened: April 2026
Agenus Clinical Trial Turnaround: SEC Closure, Class Action Dismissal, and Zydus Deal
The quarter’s strategic story is that two legal overhangs lifted while a financing piece closed.
The Securities and Exchange Commission (SEC) concluded its investigation on May 4, 2026, with no enforcement action recommended. Six weeks earlier, on March 24, 2026, the U.S. District Court for the District of Massachusetts dismissed the related securities class action in its entirety. The dismissal is not yet final: the plaintiff has appealed to the First Circuit, and that proceeding will run on its own timeline. For capital markets purposes, however, the combination of SEC closure and trial-court dismissal removes the binary disclosure risk that had complicated equity access through much of 2025.
The third piece was the Zydus Lifesciences collaboration, which closed in January 2026. It reshaped Agenus’s capital structure and manufacturing posture in a single transaction.
Zydus Lifesciences Deal Terms (Closed January 2026)
- $75M cash for the Emeryville and Berkeley biologics manufacturing facilities
- $16M equity at signing ($91M total upfront consideration)
- $7M promissory note forgiveness previously held against Agenus
- Up to $50M in contingent production milestones tied to defined BOT and BAL orders
- Territorial license covering India and Sri Lanka with royalty flow-back to Agenus
- First $20M tranche triggered March 2026 — validating the structure faster than most milestone-based partnerships deliver
Access, Pre-Commercial Revenue, and the Balance Sheet Reset
Agenus is in the unusual position of recognizing product revenue ahead of pivotal data. France’s autorisation d’accès compassionnel (AAC) framework provides reimbursed access to BOT+BAL in three settings: MSS mCRC without active liver metastases, platinum-resistant or refractory ovarian cancer, and certain advanced soft-tissue sarcomas. Paid named-patient programs are expanding across South and Central America and additional European jurisdictions. In April 2026, the company designated BAP Pharma as its global access partner to coordinate that footprint.
Pre-commercial product revenue reached $4.6 million in Q1 2026, against zero in the year-ago quarter. The strategic value of these programs extends beyond cash. Real-world mCRC patient outcomes accumulated under AAC and named-patient frameworks are increasingly relevant to European regulators evaluating conditional marketing authorizations, particularly in indications where randomized data take years to mature.
The financial reset is just as striking. Cash and equivalents stood at $35.0 million at March 31, 2026, up from $3.0 million at year-end 2025, with an additional $11.7 million in ATM (at-the-market) proceeds raised after quarter-close. Total Q1 revenue was $33.7 million versus $24.1 million in Q1 2025. The company reported net income of $39.2 million against a $26.4 million loss in the prior-year quarter — a swing largely attributable to the Zydus close. Management is now targeting an annualized operating expense run-rate of approximately $50 million. Q1 cash outflows of roughly $51.8 million were elevated by Zydus-related closing costs and pre-commercial supply build, and are not characterized as recurring.
What to Watch: BATTMAN Enrollment and mCRC Patient Outcomes
The next twelve months will determine whether Q1 2026 marked a genuine inflection or a temporary reprieve. Three items matter most.
First, BATTMAN enrollment pace. A 100-site, four-country activation curve is logistically demanding, and quarterly enrollment commentary will become the leading indicator of pivotal timing.
Second, regulatory pathway choices. Agenus’s stated intent to pursue both U.S. accelerated approval and EU conditional marketing authorization filings will hinge on how regulators weigh real-world AAC and named-patient evidence alongside randomized data.
Third, the June 2026 shareholder webcast. This is expected to offer the most direct look at how management sequences these paths.
For a company that spent two years in defensive posture, the work has shifted to execution.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada
Related Coverage:
- BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing
- BBOpCo at AACR 2026: First-Line BOT/BAL in Selected MSS Colorectal Cancer Population
- Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial
- Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer
- Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy
- Agenus Press Release on First Quarter 2026 Financial Results